# A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

> **NCT05028348** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **European Myeloma Network B.V.** · enrollment: 117 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Elotuzumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone Oral

## Key facts

- **NCT ID:** NCT05028348
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-19
- **Primary completion:** 2026-03
- **Final completion:** 2029-03
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028348, "A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT05028348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*